Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GMCSF) and Isotretinoin for Consolidation of Patients With High-Risk Neuroblastoma in First Remission. An International, Open-Label, Uncontrolled, Single-Arm, Multicenter, Phase 2 Trial

Condition:   Neuroblastoma Interventions:   Drug: Naxitamab;   Drug: GM-CSF;   Drug: Isotretinoin Sponsor:   Y-mAbs Therapeutics Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials